The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Socioeconomic position as a social determinant of health and its effect on cardiovascular outcomes and mortality in patients with prostate cancer: A SEER-Medicare based study.
 
Tarek Nahle
No Relationships to Disclose
 
Omar Elsayed
No Relationships to Disclose
 
Viraj Shah
No Relationships to Disclose
 
Harikrishnan Hyma Kunhiraman
No Relationships to Disclose
 
Sami Abi Farraj
No Relationships to Disclose
 
Priyanshu Nain
No Relationships to Disclose
 
Nickolas Stabellini
No Relationships to Disclose
 
Sadeer Al-Kindi
No Relationships to Disclose
 
Umang Swami
Consulting or Advisory Role - Adaptimmune; Astellas Pharma; AstraZeneca; Exelixis; Gilead Sciences; Imvax; Janssen Scientific Affairs; Pfizer; Sanofi; Seagen
Research Funding - Exelixis (Inst); Janssen (Inst); lava therapeutics (Inst); Loxo/Lilly (Inst); Merck (Inst); ORIC Pharmaceuticals (Inst); Seagen (Inst); Seattle Genetics/Astellas (Inst)
 
Jordan Ciuro
No Relationships to Disclose
 
Jigarkumar Parikh
Consulting or Advisory Role - Bayer
Speakers' Bureau - Bayer; Bristol-Myers Squibb; Exelixis
 
Ashanda Esdaille
Research Funding - Gilead Sciences; Gilead Sciences/Bristol Myers Squibb Foundation
Travel, Accommodations, Expenses - Gilead Sciences
 
Zachary Klaassen
No Relationships to Disclose
 
Martha Terris
No Relationships to Disclose
 
Jennifer Cullen
Patents, Royalties, Other Intellectual Property - 1. Patent #: US-20210080466-A1 Publication number: 20210080466 Title: MARKERS FOR THE DIAGNOSIS OF BIOCHEMICAL RECURRENCE IN PROSTATE CANCER Type: Application Filed: June 26, 2020 Publication date: March 18, 2021 Inventors: Michael Andrew Kiebish, Ni; Provisional Patent Application No. 62/888,890 ; Title: PROTEIN PANELS FOR THE EARLY DIAGNOSIS/PROGNOSIS OF AGGRESSIVE PROSTATE CANCER; Filed on August 19, 2019
 
Neal Weintraub
No Relationships to Disclose
 
Neeraj Agarwal
Research Funding - Amgen (Inst); Arvinas (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Celldex (Inst); crispr therapeutics (Inst); Eisai (Inst); Exelixis (Inst); Genentech (Inst); Gilead Sciences (Inst); Immunomedics (Inst); Janssen (Inst); Lilly (Inst); Merck (Inst); Nektar (Inst); ORIC Pharmaceuticals (Inst); ORIC Pharmaceuticals (Inst); Pfizer (Inst); Takeda (Inst)
Travel, Accommodations, Expenses - Exelixis; Pfizer
 
Avirup Guha
Employment - AstraZeneca (I)
Consulting or Advisory Role - Myovant Sciences; Novartis; Pfizer
Research Funding - Sumitovant Biopharma (Inst)